CICL-1 (L829)
Instructions for Use
Product information
CICL-1, identified in the cited study as Lipid 829 (L829), is an ionizable lipid used in targeted lipid nanoparticles for in vivo delivery of CAR mRNA to T cells. CD8-targeted L829 tLNPs preferentially engineered CD8-positive T cells in the reported models, produced rapid B-cell depletion, and controlled a humanized leukemia xenograft. In cynomolgus monkeys, anti-CD20 CAR mRNA tLNPs produced deep peripheral and tissue B-cell depletion, followed by repopulation dominated by naïve B cells; the authors described this finding as suggestive of immune reset. The supplied main article does not include Supplementary Table S1, so the complete five-lipid composition and N/P ratio are not presented as verified formulation values. All performance statements below are literature-reported study results, not product specifications or guaranteed outcomes.
| CAS No. | Not available |
| Chemical Name | CICL-1 (L829) |
| Formula | C55H100O14N2 |
| M.Wt | 1,013.40 |
| Purity | >98% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
Formulation & study context
Literature information refers to the cited study and its particular formulation. Administration routes are research context, not clinical instructions or a guarantee of performance.
| Component | mol% | Role |
|---|---|---|
| L829 (CICL-1) | Not reported | Ionizable lipid |
| Anti-CD8 targeting-moiety lipid conjugate (lipid identity not reported in supplied main article) | Not reported | Targeting-lipid conjugate |
| Three additional lipid components (identities not reported in supplied main article) | Not reported | Additional lipid components |
| Reported total | Not reported | Source values retained |
| N/P ratio | Not reported in the cited article |
| Total lipid:cargo weight ratio | Not reported in the supplied main article |
| Buffer & pH | Not reported in the supplied main article; formulation details are assigned to Supplementary Table S1 |
| Cargo | Anti-CD20 CAR mRNA |
| Administration route | Intravenous injection |
| Dose | 0.1-2.0 mg/kg every 72 h for three doses |
| Animal model | Cynomolgus monkeys; 22 animals across three studies |
| Formulation process | Not reported in the supplied main article; Materials and Methods and Supplementary Table S1 were not included in the uploaded PDF |
N/P is the molar ratio of specified lipid nitrogen groups to nucleic-acid phosphate groups. A lipid:cargo mass ratio is a different quantity and must not be used as N/P.
Stock-solution preparation table
Calculated from the product-page molecular weight: 1013.4 g/mol. Volumes are final solution volumes.
| Lipid mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 9.868 mL | 1.974 mL | 0.987 mL |
| 25 mg | 24.669 mL | 4.934 mL | 2.467 mL |
| 50 mg | 49.339 mL | 9.868 mL | 4.934 mL |
| 100 mg | 98.678 mL | 19.736 mL | 9.868 mL |
| 250 mg | 246.694 mL | 49.339 mL | 24.669 mL |
Volume (mL) = mass (mg) × 1000 / [MW (g/mol) × concentration (mM)]. These are mathematical conversions, not measured solubility or validated solvent recommendations. Confirm solvent compatibility and the molecular weight of the exact material before use.
Open editable solution calculators →Handling & storage
Provided that storage conditions are as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 1 year.
Wherever possible, prepare and use solutions on the same day. If stock solutions must be prepared in advance, store them as aliquots in tightly sealed vials at -20°C. Generally, these will be usable for up to one month.
Before use, and prior to opening the vial, allow the product to equilibrate to room temperature for at least 1 hour.
References
Cited literature for this formulation and performance dataset Hunter TL, Bao Y, Zhang Y, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311-1317. DOI: 10.1126/science.ads8473 Identity and performance: supplied Science main article, Figures 1 and 3-5. The complete five-lipid composition, preparation method and particle-characterization details are assigned by the article to Supplementary Table S1 and Materials and Methods, which were not present in the uploaded PDF.